More than two decades ago, the presence of naturally occurring soluble HLA class I molecules (sHLA-I) in the The ability to predict the likely occurrence of graftsera of healthy individuals was reported by van Rood et al 2 versus-host-disease (GVHD) after BMT would be and Charlton and Zmijewski. 3 Both groups defined these extremely valuable. We performed a retrospective study sHLA-I molecules by inhibition of HLA-specific alloantion the correlation between soluble HLA class I (sHLAsera in a complement-dependent cytotoxicity assay. sHLA-I) levels and GVHD in the sera of 34 patients receiving I can be detected in virtually all body fluids. 4 Serum HLA an allogeneic BMT and in the sera of 12 patients receivlevels are fairly constant in normal individuals and range ing an autologous BMT. sHLA-I levels measured prebetween 0.5 and 25 g/ml.
Patients
Relapse of the original disease was confirmed histologically by bone marrow aspirate and, if possible, genetically by Forty-six adult patients who underwent BMT between 1978 the presence of Philadelphia chromosome-positive cells. and 1990 in the Leiden University Hospital were included Infections comprised both viral (CMV, VZV, HSV), bacin this study. Thirty-three patients received bone marrow terial (sepsis, pneumonitis) and generalized candida infecfrom an HLA-identical sibling, one patient (UPN 30) tions. received bone marrow from her HLA-identical father and 12 patients received autologous bone marrow. Of the Sera patients receiving allogeneic bone marrow (21 females, 13 males) the mean age was 27 years (range . Table 1 Serum samples were collected before BMT and after BMT. Post-BMT serum samples were collected systematically for summarizes relevant clinical information on the allogeneic BMT patients.The mean age of the patients receiving autothe first 3 months post-BMT, and thereafter incidentally up to 3 years post-BMT. Serum samples were also collected logous bone marrow (five females and seven males) was 37 (range 20-58). Table 2 summarizes the data on the autofrom BMT donors and healthy blood donors. All sera were stored at −30°C until further use. For this study, we logous BMT patients. Normal levels of sHLA-I were determined in bone marrow donors and healthy blood attempted to include at least one sample for every 10-day period post-BMT until day 100 and during complications. donors (n = 36). 
sHLA-I ELISA Statistical analysis
Serum levels of sHLA-I were assessed using the following Since serum sHLA-I levels vary widely between individmethod. Microtiter plates (Greiner, Rijn, The Netherlands) uals, the values are reported in figures as changes in sHLAwere coated with goat-anti-mouse IgG (Jackson, West I level using the formula: ⌬sHLA-I = [post-BMT Grove, PA, USA), diluted 1:500 for 1 h at room temperaconcentration] − [pre-BMT concentration]. 24 To test for difture. Plates were then incubated with the monoclonal antiferences in sHLA-I levels of healthy controls and pre-BMT body TP25.99, directed against the ␣3 domain of HLA sHLA-I levels of BMT patients, t-tests were used. Differclass I (a kind gift of Prof Ferrone, Valhalla, New York, ences between autologous BMT patients and allogeneic USA) (5 g/ml, 60 min at 37°C), washed and blocked with BMT patients in changes in sHLA-I levels from pre-to phosphate-buffered saline (PBS)/0.05% Tween/1% bovine post-BMT were determined with the repeated measureserum albumin (BSA) for 30 min at 37°C). Two g EDTA ments multivariate analysis of variance (MANOVA). For were added to 100 l serum and briefly centrifuged. Plates this analysis, data were only used if no aGVHD or cGVHD were washed, and sera, diluted 1:80 or 1:200 in PBS/0.05% was present. Technically speaking, in this MANOVA the Tween/1% BSA, were incubated for 16-18 h (100 l/well, interaction between the BMT group and pre-post treatment 4°C). After washing the plates with PBS/0.05% Tween, is tested after correction for the factor 'patients'. By taking 100 l rabbit-anti-human ␤2m (ACSC) were added to the 'patients' as a factor in the MANOVA, a correction for wells (1:10 000, 60 min, 37°C). Finally, plates were washed general patient levels is carried out. To determine the correand incubated with a goat-anti-rabbit Ig conjugated with lation of different clinical complications with changes in horse radish peroxidase (Sigma, Bornem, Belgium) (1:1000, 60 min, 37°C). Bound antibody was detected by sHLA-I levels within the allogeneic BMT group, compliusing 1,2-phenylenediamine (OPD; DAKO, Glostrup, cations were coded into the following dichotomous variDenmark) as a substrate. The reaction was stopped with ables: 'relapse' = absence (0) vs presence of relapse (1), 2.5 n H 2 SO 4 and absorbance was read at 492 nm. Different 'aGVHD' = grades 0-1 (0) vs grades II-IV (1), dilutions of a control serum with a known concentration of 'cGVHD' = absence (0) vs mild or severe cGVHD (1) and sHLA-I were used as standard. All samples from an indi-'infection' = absence (0) vs bacterial, viral or fungal infecvidual were tested in the same experiment to minimize tion (1). The statement used in the MANOVA is the followinter-assay variation.
ing: ⌬sHLA-I BY patients (1 34) WITH relapse, aGVHD, cGVHD, infection. Thus only the changes within patients are used and not the differences between patient groups.
sHLA-I levels and liver GVHD
This analysis can be seen as an extension of the well-known To evaluate the contribution of liver GVHD to increased paired t-test. The correlation between changes in sHLA-I sHLA-I levels, total blood bilirubin levels were used as a levels and changes in bilirubin levels within selected marker for the occurrence of liver GVHD. 23 For this analypatients was obtained in a truly multivariate MANOVA sis patients were selected who suffered from GVHD grades with 'patients' as factor and 10 log(bili) and ⌬sHLA-I as II-IV and whose bilirubin levels were known (n = 13). Bilioutcome variables. P values Ͻ0.05 were accepted as rubin data were converted to their 10 log-value ( 10 log(bili)). significant. All data on sHLA-I and bilirubin levels from these patients were correlated as described below. Results 0.94 g/ml and 18.73 g/ml (mean 4.81 ± 4.30 g/ml).
The pre-BMT sHLA-I levels of 12 patients receiving autosHLA-I class I levels in healthy individuals and in BMT logous BMT ranged between 1.64 g/ml and 17.33 g/ml recipients before BMT (mean 6.59 ± 5.36 g/ml) and the pre-BMT levels of 34 Normal sHLA-I levels were determined in a total of 36 allogeneic BMT patients ranged between 0.28 g/ml and healthy blood and bone marrow donors and ranged between 16 .85 g/ml (mean 4.07 ± 3.50 g/ml). The differences in sHLA-I levels of healthy blood and bone marrow donors 4.5 g/ml of the pre-BMT level with the exception of ⌬sHLA-I of two patients (UPNs 45 and 54) whose sHLAand autologous or allogeneic BMT patients pre-BMT were not significant (data not shown).
I decreased post-BMT. sHLA-I levels of both patients returned to pre-BMT value after approximately 60 days post-BMT (Figure 1a ). No significant difference in uncomPost-BMT sHLA-I levels in autologous and allogeneic plicated post-BMT ⌬sHLA-I levels was found between BMT patients autologous and allogeneic BMT recipients. The sHLA-I levels of autologous BMT patients remained sHLA-I levels of patients without GVHD and patients quite stable after BMT. ⌬sHLA-I levels remained within with aGVHD grade I showed some fluctuation, although sHLA-I levels increase more than during bacterial or fungal
For each complication the total allogeneic BMT group is divided into infections, although none of these increases was signifipatients who did not suffer at all from that complication during any of the time-points measured and patients who suffered from that complication cant ( Figure 2 ). of aGVHD and the ⌬sHLA-I (data not shown).
The effect of liver GVHD on sHLA-I levels ⌬sHLA-I levels also remained within 4.5 g/ml of the pre-BMT level (Figure 1b) . In two patients with aGVHD grade
We investigated whether GVHD of the liver has a signifi-I (UPNs 11 and 12) the sHLA-I levels increased above this cant influence on the sHLA-I levels. Blood bilirubin levels threshold around day 200. In both cases no sign of GVHD were used as a marker for liver GVHD and correlated with was found, but the increase in sHLA-I level correspon-⌬HLA-I levels. The results are shown in Figure 3 . denced to a viral infection. Recipients of allogeneic marrow MANOVA analysis revealed a slight, but significant correwho relapsed maintained stable levels (Figure 1c) , which lation between bilirubin and ⌬sHLA-I levels (R = 0.282, was also observed in recipients of autologous marrow who P = 0.037). relapsed ( Figure 1a , UPNs 47, 48 and 53). In most patients suffering from either aGVHD grades II-IV or cGVHD, sHLA-I levels reached levels above the threshold of Discussion 4.5 g/ml (Figure 1d) .
Our results show that the conditioning regimen and BMT itself do not have a significant effect on sHLA-I levels in sHLA-I levels during post-BMT complications autologous or allogeneic BMT patients. After BMT the The effects of post-BMT complications were further analyzed in the allogeneic recipients. This group can be divided into patients who never suffered from a given complication and patients who suffered from that complication during at least one post-BMT time-point measured. Data from the latter group is obtained in the absence or presence of that complication. Summary statistics of these subgroups are given in Table 3 .
Changes in sHLA-I levels during different complications were analyzed in the MANOVA analysis as described in the Material and methods section. The results from the MANOVA analysis are summarized in Table 4 . Significantly, increased sHLA-I levels were found during aGVHD and cGVHD (P = 0.004 and P = 0.005, respectively) and during relapse (P = 0.032). Although sHLA-I levels rise during infection, this increase is not significant. Also, in the autologous BMT patients, infections do not cause a sig- ent kinds of infections showed that during viral infections,
In our retrospective study, infections did not have a significant influence on sHLA-I levels. Since viral infections upregulate IFN␥ production, that in turn can increase the release of sHLA-I, and increased sHLA-I levels during viral infections are to be expected. When analyzing the different kinds of infections separately, viral infections increase sHLA-I levels the most, although not significantly. In our study, infections have only been recorded when the patient showed signs of active infection. If sHLA-I levels do not start rising during the active infection, but earlier or later in the follow-up, no correlation is found in our analysis. In a prospectively designed study, Puppo et al 22 found an increase in sHLA-I levels 2 weeks after onset of infection. However, they only considered patients suffering from GVHD and compared sHLA-I levels in patients with and ter results and ours may well lie in the design of the studies.
(y-axis, log-scale). The correlation coefficient and the P value, obtained
Our data show that GVHD and infections differ in their in the MANOVA as described in the Material and methods section, show a weak, but statistically significant correlation.
ability to increase sHLA-I. While GVHD episodes have a profound effect on sHLA-I levels, the effect of infections is less prominent. Puppo et al 22 showed in their group of sHLA-I levels of autologous and allogeneic BMT patients with GVHD grades 0-I remain fairly stable. In patients suf-BMT patients that sHLA-I levels are higher during GVHD than during infections. Both GVHD and infections lead to fering from aGVHD grades II-IV or cGVHD, significantly increased sHLA-I levels were found. sHLA-I levels during an activation of the immune system. During GVHD, however, more tissue damage will occur than during infections, relapse were also significantly increased. This group, however, consisted of six patients, of whom one relapsed while suggesting that release of sHLA-I molecules by damaged tissue contributes significantly to increased sHLA-I levels suffering from severe cGVHD. Therefore, these results should be interpreted with care. Although an increment of during GVHD. The biological function of sHLA-I is still unknown, sHLA-I level was observed, infections did not affect sHLA-I levels significantly.
though it has been shown that sHLA-I can down-regulate both cellular and humoral responses. 24, 28, 29 A recent study The increase in sHLA-I during GVHD may be explained by two mechanisms. Firstly, activation of donor bone marby Zavazava and Krönke 30 showed that sHLA acts in vitro on T cells by promoting apoptosis of activated, Fasrow-derived cells in the course of GVHD may lead to enhanced release of sHLA-I by these cells. Enhanced proexpressing T cells through the upregulation of Fas ligand in an allospecific fashion. Although the studies performed duction of endogenous cytokines might underlie the increased sHLA-I production by activated donor-derived so far in BMT patients show that increased sHLA-I levels correlate well with GVHD activity, its modulating properimmune cells. Therapeutic use of recombinant interferon-␥ (IFN␥) has been shown to increase sHLA-I levels 25, 26 and ties in the GVH reactivities remain to be established. it has been suggested that tumor necrosis factor ␣ (TNF␣) might have a similar effect. 9 Since both IFN␥ and TNF␣ have been implicated in the pathogenesis of GVHD, 27 the
